BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 2548620)

  • 1. Inhibition of cyclic AMP phosphodiesterase activity of human blood platelet membrane by ADP.
    Kahn NN; Sinha AK
    Biochim Biophys Acta; 1989 Aug; 984(1):113-8. PubMed ID: 2548620
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of human platelet cyclic AMP phosphodiesterase and of platelet aggregation by a hemisynthetic flavonoid, amentoflavone hexaacetate.
    Beretz A; Briançon-Scheid F; Stierlé A; Corre G; Anton R; Cazenave JP
    Biochem Pharmacol; 1986 Jan; 35(2):257-62. PubMed ID: 3002388
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of cAMP phosphodiesterase inhibitors on ADP-induced shape change, cAMP and nucleoside diphosphokinase activity of rabbit platelets.
    Lam SC; Guccione MA; Packham MA; Mustard JF
    Thromb Haemost; 1982 Apr; 47(2):90-5. PubMed ID: 6285543
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potentiation of antiaggregating activity of adenosine by a phosphodiesterase inhibitor, EG626 (oxagrelate), in human platelets in vitro.
    Azuma H; Takashima Y; Ishikawa M; Yamakado T
    Jpn J Pharmacol; 1984 Feb; 34(2):159-70. PubMed ID: 6205194
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mepacrine-induced inhibition of human platelet cyclic-GMP phosphodiesterase.
    Yamakado T; Tanaka F; Hidaka H
    Biochim Biophys Acta; 1984 Sep; 801(1):111-6. PubMed ID: 6147162
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of SK&F 94120, an inhibitor of cyclic nucleotide phosphodiesterase type III, on human platelets.
    Simpson AW; Reeves ML; Rink TJ
    Biochem Pharmacol; 1988 Jun; 37(12):2315-20. PubMed ID: 2455518
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 2-Methylthioadenosine[beta-32P]diphosphate. An agonist and radioligand for the receptor that inhibits the accumulation of cyclic AMP in intact blood platelets.
    Macfarlane DE; Srivastava PC; Mills DC
    J Clin Invest; 1983 Mar; 71(3):420-8. PubMed ID: 6298277
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cyclic nucleotides and platelet aggregation. Effect of aggregating agents on the activity of cyclic nucleotide-metabolizing enzymes.
    Barber AJ
    Biochim Biophys Acta; 1976 Sep; 444(2):579-95. PubMed ID: 9149
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of adenylate cyclase by adenosine analogues in preparations of broken and intact human platelets. Evidence for the unidirectional control of platelet function by cyclic AMP.
    Haslam RJ; Davidson MM; Desjardins JV
    Biochem J; 1978 Oct; 176(1):83-95. PubMed ID: 215136
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 7-Bromo-1,5-dihydro-3,6-dimethylimidazo[2,1-b]quinazolin-2(3H)- one (Ro 15-2041), a potent antithrombotic agent that selectively inhibits platelet cyclic AMP-phosphodiesterase.
    Muggli R; Tschopp TB; Mittelholzer E; Baumgartner HR
    J Pharmacol Exp Ther; 1985 Oct; 235(1):212-9. PubMed ID: 2995647
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Octimibate, a potent non-prostanoid inhibitor of platelet aggregation, acts via the prostacyclin receptor.
    Merritt JE; Hallam TJ; Brown AM; Boyfield I; Cooper DG; Hickey DM; Jaxa-Chamiec AA; Kaumann AJ; Keen M; Kelly E
    Br J Pharmacol; 1991 Jan; 102(1):251-9. PubMed ID: 1710526
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of human platelet aggregation by dihydropyrano- and dihydrofuranocoumarins, a new class of cAMP-phosphodiesterase inhibitors.
    Thastrup O; Knudsen JB; Lemmich J; Winther K
    Biochem Pharmacol; 1985 Jun; 34(12):2137-40. PubMed ID: 2988567
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Purification of cyclic adenosine monophosphate phosphodiesterase from human platelets using new-inhibitor Sepharose chromatography.
    Umekawa H; Tanaka T; Kimura Y; Hidaka H
    Biochem Pharmacol; 1984 Nov; 33(21):3339-44. PubMed ID: 6093810
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of rabbit platelet phosphodiesterase activity and aggregation by calcium channel blockers.
    Moore JB; Fuller BL; Falotico R; Tolman EL
    Thromb Res; 1985 Nov; 40(3):401-11. PubMed ID: 2417362
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Specific inhibition of ADP-induced platelet aggregation by clopidogrel in vitro.
    Weber AA; Reimann S; Schrör K
    Br J Pharmacol; 1999 Jan; 126(2):415-20. PubMed ID: 10077233
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of suramin on increases in cytosolic calcium and on inhibition of adenylate cyclase induced by adenosine 5'-diphosphate in human platelets.
    Hall DA; Hourani SM
    Biochem Pharmacol; 1994 Mar; 47(6):1013-8. PubMed ID: 8147900
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HL 725, an extremely potent inhibitor of platelet phosphodiesterase and induced platelet aggregation in vitro.
    Ruppert D; Weithmann KU
    Life Sci; 1982 Nov; 31(19):2037-43. PubMed ID: 6294426
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selective inhibitor of platelet cyclic adenosine monophosphate phosphodiesterase, cilostamide, inhibits platelet aggregation.
    Hidaka H; Hayashi H; Kohri H; Kimura Y; Hosokawa T; Igawa T; Saitoh Y
    J Pharmacol Exp Ther; 1979 Oct; 211(1):26-30. PubMed ID: 226672
    [No Abstract]   [Full Text] [Related]  

  • 19. Interactions between prostaglandin E2 and inhibitors of platelet aggregation which act through cyclic AMP.
    Gray SJ; Heptinstall S
    Eur J Pharmacol; 1991 Feb; 194(1):63-70. PubMed ID: 1647965
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potentiation of the antiplatelet action of adenosine in whole blood by dipyridamole or dilazep and the cAMP phosphodiesterase inhibitor, RA 233.
    Dawicki DD; Agarwal KC; Parks RE
    Thromb Res; 1986 Jul; 43(2):161-75. PubMed ID: 3016942
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.